Drug Discovery

Axiogenesis claims that its Cor.At murine ESC-derived cardiomyocytes represent the first physiologically relevant disease model of cardiomyopathy.

Structural analysis of 8ANC195, a broadly neutralizing antibody against HIV, revealed a new conformation of the virus’s signature envelope protein. The antibody is shown...

Scientists at Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard, discovered a potential new target for malignant brain tumor immunotherapy. The results of their studies showed that the immune cell surface receptor, CD161, suppresses the cancer-fighting activity of immune T cells, and is activated by its ligand, CLEC2D, on tumor cells and immune-suppressing cells in the brain. Their studies further demonstrated how blocking this pathway increased T cell-mediated killing of glioma cells in vitro and their anti-tumor function in animal models.

AstraZeneca has agreed to sell worldwide (excluding Japan) rights to its migraine drug Zomig® (zolmitriptan) to Germany-based Grünenthal for $200 million upfront and potentially...

A Stanford researcher's advance might enable patients with diabetes to take a double-acting shot that contains insulin in combination with a drug based on a second hormone, amylin, which plays a synergistic role with insulin to control blood sugar levels after eating in a way that is more effective than insulin alone and mimics what occurs naturally with a meal.

Emergent separately confirms start of Phase II study with TRU-016 in CLL patients.

Three different methods allow large-scale expansion of clinically relevant quantities of immunosuppressive T cells.

Overall, the top 10 pharma companies on this year’s GEN list generated a combined $1.792 trillion in market cap,is down 2.9% fromGEN’s A-List of Top 10 Pharma Companies of 2018, but up 4% from the Top 10 Pharma Companies of 2017, a year in which pharma stocks recovered from the previous year’s election-related investor fears of curbs on rising prescription drug prices. If nothing else, those results confirm the age-old advice that stock investors should think long-term if they want the best results.

Bubbly extracellular vesicles could become mini treatment transporters, carrying a combination of therapeutic drugs and genes that target cancer cells and kill them, according to new research from Michigan State University and Stanford University.

In response to the global COVID-19 pandemic, vaccine research and manufacturing processes have seen unprecedented advancements over a short timeframe. This eBook, sponsored by Sartorius, explores the latest methodologies and suggests alternative strategies in the development of future vaccines to fight the huge variety of infectious diseases.